Pfizer to buy weight-loss drug developer Metsera

Pfizer He said he would get a drug producer on Monday. Metsera In an agreement up to $ 7.3 billion, including future payments, the exploding obesity is trying to gain a slice in the pharmaceutical market.

Pfizer said that Biotech Company would pay the first $ 47.50 cash for Metsera, which is about 43% premium for the closing price of $ 33.32 on Friday. This gives the agreement a $ 4.9 billion business value.

PACT also contains a conditional value up to $ 22.50, based on potential clinical and regulatory achievements that can bring the total value to $ 70 for Metsera’s drugs.

The agreement is expected to close at the end of the year. METSERA shares rose by more than 60% in the premmarket trade on Monday, while Pfizer’s shares increased by more than 1%.

The movement comes after a number of setbacks for Pfizer in the Obseity area. The pharmaceutical giant fought to develop his own lead obesity drug candidate Danuglpron before deciding to scrape completely in April due to security concerns. Pfizer also left a different pill once a day in June 2023 due to high liver enzymes in patients receiving it.

Pfizer has an earlier stage obesity drugs that work in different ways on the pipeline, but the company has faced investor pressure to accelerate its release.

The opportunity can be too big. Some analysts are waiting for the weight loss medication area to be worth approximately 100 billion dollars until the 2030s, and the place to compete with popular injections with new competitors Hand Lilly And Novo Nordisk.

Founded in 2022, Metsera brings a pipeline of both oral and injected treatments with different targets that the company has obtained through its own licensing and purchasing agreements. This contains a GLP-1 drug called Met-233i, which helps patients lose their weight up to 8.4% of their weight in a small, early stage attempt within 36 days. METSERA develops this treatment once once injected, that is, patients can use it less often than existing weekly injections.

Metsera’s pipeline includes a monthly medicine targeting a hormone called Amylin, and two oral GLP-1 candidates, “which is expected to start close to trials.”

Pfizer CEO Albert Bourla said in a statement, “the purchasing of the proposed Metsera focuses on directing our investments to the most effective opportunities and push Pfizer to this key therapeutic field.” He said. “We are excited to implement our deep cardiometabolic experience, production and commercial infrastructure to accelerate a potential injectable portfolio in its class.”

In a note on Monday, Leerink Partners Analyst David Risinger said that the company’s Metsera’s obesity candidates have the potential to produce more than 5 billion dollars in total annual higher sales. In a separate note on Monday, JPMorgan Analyst Chris Schott said Metsera’s experimental drugs should “accelerate Pfizer’s entry into the market”.

The New York -based Metsera was opened to the public this year in one of the largest biotechnology lists of 2025. Following the success of weekly injections such as Eli Lilly’s Obesity Pharmaceutical Zepbound and Novo Nordisk’s rival Wegovy, a few companies competing to improve the new generation of obesity treatments.